Study guide

5.3 Endocrine, Renal, and Gastrointestinal Pathophysiology

PEBC Pharmacist Evaluating Examination Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Introduction & The Canadian Pharmacy Practice Landscape

1.1 PEBC EE Blueprint, Format, Scoring, and IPG Certification Pathway 1.2 The Canadian Healthcare System, Canada Health Act, and Drug Regulation 1.3 Canadian Pharmacy Regulatory Framework, NAPRA Standards, and Professional Legislation

2 Chapter 2: Pharmaceutics & Drug Delivery Systems

2.1 Physicochemical Principles, Solubility, Ionization, and Stability 2.2 Solid Dosage Forms, Formulation Science, and Modified-Release Technologies 2.3 Liquid and Semisolid Dosage Forms, Dispersions, and Topical Delivery 2.4 Sterile Product Principles, Parenteral Delivery, and Biopharmaceuticals 2.5 Pharmaceutical Quality: GMP, Stability Testing, and Bioequivalence

3 Chapter 3: Biopharmaceutics & Clinical Pharmacokinetics

3.1 Drug Absorption, Distribution, Metabolism, and Elimination (ADME) 3.2 Bioavailability, Bioequivalence, and Biopharmaceutics Classification System (BCS) 3.3 Pharmacokinetic Modeling, Parameters, and Dosing Calculations 3.4 Therapeutic Drug Monitoring (TDM) and Clinical Application

4 Chapter 4: Pharmacology, Toxicology & Pharmacogenetics

4.1 Autonomic and Central Nervous System Pharmacology 4.2 Cardiovascular, Renal, and Endocrine Pharmacology 4.3 Clinical Toxicology, Overdose Management, and Antidotes 4.4 Biologics, Biosimilars, and Pharmacogenetics

5 Chapter 5: Pathophysiology & Clinical Assessment

5.1 Clinical Laboratory Diagnostics, Biomarkers, and Vital Signs 5.2 Cardiovascular and Respiratory Pathophysiology 5.3 Endocrine, Renal, and Gastrointestinal Pathophysiology 5.4 Neurologic, Psychiatric, and Musculoskeletal Pathophysiology 5.5 Physical Assessment and Point-of-Care Testing

6 Chapter 6: Pharmacotherapy & Minor Ailments

6.1 Cardiovascular Pharmacotherapy & Evidence-Based Guidelines 6.2 Endocrine and Metabolic Pharmacotherapy 6.3 Infectious Diseases and Antimicrobial Stewardship 6.4 Neurologic, Psychiatric, and Pain Management Therapeutics 6.5 Minor Ailment Prescribing and Nonprescription Therapy 6.6 Respiratory Pharmacotherapy: Asthma, COPD, and Inhaled Therapy 6.7 Gastrointestinal and Hepatic Pharmacotherapy 6.8 Renal, Fluid, and Electrolyte Therapeutics 6.9 Musculoskeletal and Rheumatologic Pharmacotherapy 6.10 Dermatologic, Ophthalmic, and Ear-Nose-Throat Pharmacotherapy 6.11 Hematologic, Immunologic, and Oncology Supportive Care 6.12 Women's Health, Men's Health, and Urologic Therapeutics 6.13 Nutrition, Natural Health Products, and Complementary Medicine

7 Chapter 7: Special Populations & Applied Therapeutics

7.1 Geriatric Pharmacotherapy and Deprescribing 7.2 Pediatric and Neonatal Pharmacotherapy 7.3 Perinatal Pharmacotherapy: Pregnancy and Lactation 7.4 Dosage Adjustments in Renal and Hepatic Impairment

8 Chapter 8: Prescription Processing, Calculations & Compounding

8.1 Prescription Processing, Verification, and Drug Therapy Problem Management 8.2 Pharmaceutical Calculations and Clinical Math 8.3 Non-Sterile Compounding and NAPRA Standards 8.4 Sterile and Hazardous Compounding under NAPRA Standards 8.5 Advanced Calculations: Infusion Rates, Parenteral Nutrition, and Renal Estimation

9 Chapter 9: Health Equity, Indigenous Health & Pharmacy Bioethics

9.1 Social Determinants of Health and Health Equity 9.2 Indigenous Health, Cultural Safety, and Humility 9.3 Pharmacy Bioethics, Informed Consent, and Professional Boundaries 9.4 Health Promotion, Disease Prevention, and Public Health

10 Chapter 10: Evidence Appraisal, Safety & Practice Management

10.1 Biostatistics and Critical Appraisal of Clinical Literature 10.2 Pharmacoeconomics and Pharmacoepidemiology 10.3 Medication Safety, Incident Analysis, and Quality Improvement 10.4 Pharmacy Operations, Cold-Chain Management, and Emergency Preparedness 10.5 Drug Information and Evidence-Based Decision Making 10.6 Pharmacovigilance and Adverse Drug Reaction Reporting in Canada

11 Chapter 11: Patient Care Process, Communication & Collaborative Practice

11.1 The Patient Care Process: Assessment, Care Plans, and Follow-Up 11.2 Patient and Caregiver Communication, Education, and Health Literacy 11.3 Motivational Interviewing and Shared Decision-Making 11.4 Intra- and Interprofessional Collaborative Care

12 Chapter 12: Medication Administration, Devices & Expanded Scope

12.1 Injection and Vaccine Administration Technique 12.2 Immunization Schedules, Vaccine Selection, and Travel Health 12.3 Home Medical Devices and Device Technique Coaching 12.4 Expanded Scope: Adapting, Renewing, Initiating, and Medication Reconciliation

13 Chapter 13: Pharmacy Management, Finance & Practice Leadership

13.1 Human Resources, Leadership, and Change Management 13.2 Financial Management, Drug Plans, and Marketing 13.3 Quality Improvement, Risk Management, and Workplace Safety

5.3 Endocrine, Renal, and Gastrointestinal Pathophysiology

Key Takeaways Explain This Topic AI

Type 1 diabetes results from autoimmune destruction of pancreatic beta-cells causing absolute insulin deficiency, whereas Type 2 diabetes involves progressive insulin resistance coupled with relative beta-cell secretory failure.

Diabetic Ketoacidosis (DKA) is characterized by severe ketonemia and high anion gap metabolic acidosis driven by lipolysis, whereas Hyperglycemic Hyperosmolar State (HHS) is characterized by extreme hyperglycemia (> 33.3 mmol/L) and profound hyperosmolality without significant ketoacidosis.

Pre-renal acute kidney injury features preserved tubular function with a fractional excretion of sodium (FeNa) < 1% and BUN:SCr ratio > 20:1, whereas intrinsic Acute Tubular Necrosis (ATN) exhibits tubular epithelial necrosis, muddy brown granular casts, and FeNa > 2%.

Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) develops as impaired renal phosphate excretion and diminished calcitriol (1,25-dihydroxyvitamin D) synthesis trigger secondary hyperparathyroidism.

Ulcerative colitis causes continuous mucosal inflammation restricted to the colon and rectum, whereas Crohn's disease causes transmural, granulomatous inflammation with skip lesions throughout any portion of the gastrointestinal tract.

Last updated: August 2026

5.3 Endocrine, Renal, and Gastrointestinal Pathophysiology

Exam Focus: Endocrine, renal, and gastrointestinal disorders involve complex hormonal feedback mechanisms, nephron transport dynamics, and epithelial barrier function. Candidates must understand the pathophysiological distinctions between DKA and HHS, the cellular mechanisms of CKD-Mineral and Bone Disorder (CKD-MBD), the differential diagnosis of Acute Kidney Injury (AKI), and the clinical characteristics distinguishing Crohn's disease from ulcerative colitis.

Endocrine Pathophysiology

1. Diabetes Mellitus: Type 1 vs Type 2 Pathogenesis +-------------------------------------------------------------------------+

  • | PATHOPHYSIOLOGY OF DIABETES MELLITUS |
  • +-------------------------------------------------------------------------+
  • | |
  • | [TYPE 1 DIABETES] [TYPE 2 DIABETES] |
  • | - T-cell autoimmune insulitis - Peripheral insulin resistance |
  • | - Autoantibodies (anti-GAD65, IA-2) - Hepatic gluconeogenesis excess|
  • | - Absolute insulin deficiency - Relative beta-cell failure |
  • | - Ketosis-prone (DKA) - Hyperosmolar-prone (HHS) |
  • | - Onset: Children/young adults - Onset: Adults, obesity-linked |
  • | |
  • +-------------------------------------------------------------------------+

Type 1 Diabetes Mellitus (T1DM): Cell-mediated autoimmune destruction of insulin-producing β \beta β -cells within pancreatic islets of Langerhans. Characterized by circulating autoantibodies: Glutamic Acid Decarboxylase ( G A D 65 GAD_{65} G A D 65 ​ ), Islet Antigen-2 ( I A - 2 IA\text{-}2 I A - 2 ), Insulin Autoantibodies ( I A A IAA I AA ), and Zinc Transporter 8 ( Z n T 8 ZnT8 Z n T 8 ). Results in absolute insulin deficiency ; patients require lifelong exogenous insulin to survive and prevent ketosis.

Type 2 Diabetes Mellitus (T2DM): Heterogeneous disorder characterized by progressive insulin resistance in peripheral tissues (skeletal muscle, liver, adipose) combined with progressive β \beta β -cell secretory dysfunction :

Muscle: Impaired insulin-stimulated GLUT4 translocation reduces peripheral glucose uptake.

Liver: Insulin fails to suppress hepatic gluconeogenesis and glycogenolysis, producing fasting hyperglycemia.

Adipose Tissue: Accelerated lipolysis elevates circulating free fatty acids (FFAs), driving hepatic steatosis, muscle lipotoxicity, and worsening insulin resistance.

Incretin Defect: Blunted postprandial Glucagon-Like Peptide-1 (GLP-1) and Glucose-Dependent Insulinotropic Polypeptide (GIP) secretion and action, coupled with unsuppressed postprandial glucagon secretion by pancreatic α \alpha α -cells.

Diagnostic Criteria (Diabetes Canada):

Fasting Plasma Glucose (FPG) ≥ 7.0 mmol/L \ge 7.0\text{ mmol/L} ≥ 7.0 mmol/L (fasting ≥ 8 hours \ge 8\text{ hours} ≥ 8 hours ).

Glycated Hemoglobin (HbA1c) ≥ 6.5 % \ge 6.5\% ≥ 6.5% (standardized NGSP assay).

2-Hour Plasma Glucose (2hPG) ≥ 11.1 mmol/L \ge 11.1\text{ mmol/L} ≥ 11.1 mmol/L in a 75 g 75\text{ g} 75 g Oral Glucose Tolerance Test (OGTT).

Random Plasma Glucose ≥ 11.1 mmol/L \ge 11.1\text{ mmol/L} ≥ 11.1 mmol/L in the presence of classic symptoms (polyuria, polydipsia, unexplained weight loss).

2. Acute Metabolic Emergencies: DKA vs HHS

  • Clinical Parameter Diabetic Ketoacidosis (DKA) Hyperglycemic Hyperosmolar State (HHS)
  • Primary Population Typically Type 1 Diabetes Typically Type 2 Diabetes (elderly, institutionalized)
  • Onset Speed Rapid ( < 24 hours < 24\text{ hours} < 24 hours ) Insidious over days to weeks

Pathophysiologic Trigger Absolute insulin deficiency + surge in counter-regulatory hormones (glucagon, epinephrine, cortisol) Relative insulin deficiency (enough to suppress lipolysis; insufficient for glucose utilization)

Plasma Glucose Usually 14.0 to 28.0 mmol/L 14.0\text{ to }28.0\text{ mmol/L} 14.0 to 28.0 mmol/L Markedly Elevated ( > 33.3 mmol/L > 33.3\text{ mmol/L} > 33.3 mmol/L )

Arterial pH Acidemic ( pH < 7.30 \text{pH} < 7.30 pH < 7.30 ; severe < 7.00 < 7.00 < 7.00 ) Normal ( pH > 7.30 \text{pH} > 7.30 pH > 7.30 )

Serum Bicarbonate Low ( < 18 mmol/L < 18\text{ mmol/L} < 18 mmol/L ; severe < 10 mmol/L < 10\text{ mmol/L} < 10 mmol/L ) Normal ( > 18 mmol/L > 18\text{ mmol/L} > 18 mmol/L )

Ketones (Urine/Serum) Strongly Positive ( β \beta β -hydroxybutyrate) Negative or Trace

Serum Osmolality Variable ( < 320 mOsm/kg < 320\text{ mOsm/kg} < 320 mOsm/kg ) Severely Elevated ( > 320 mOsm/kg > 320\text{ mOsm/kg} > 320 mOsm/kg )

Serum Anion Gap High ( > 12 mmol/L > 12\text{ mmol/L} > 12 mmol/L ) Normal ( < 12 mmol/L < 12\text{ mmol/L} < 12 mmol/L )

Clinical Hallmarks Kussmaul respirations (hyperventilation), fruity acetone breath, abdominal pain, vomiting Profound dehydration, altered sensorium, stupor, coma, focal neurologic signs

3. Thyroid and Adrenal Pathophysiology

Hypothyroidism:

Primary (Hashimoto's Thyroiditis): Autoimmune destruction of thyroid follicular cells mediated by anti-thyroid peroxidase (anti-TPO) and anti-thyroglobulin (anti-Tg) antibodies. Laboratory profile: Elevated TSH, Low Free T4 . Features: fatigue, cold intolerance, weight gain, constipation, dry skin, bradycardia, delayed deep tendon reflex relaxation, myxedema.

Secondary/Tertiary: Pituitary or hypothalamic failure. Laboratory profile: Low/Normal TSH with Low Free T4.

Hyperthyroidism / Thyrotoxicosis:

Graves' Disease: Autoimmune disorder caused by Thyroid-Stimulating Immunoglobulins (TSI / TRAb) that bind to and activate TSH receptors, stimulating autonomous thyroid hormone synthesis. Laboratory profile: Suppressed/Undetectable TSH ( < 0.01 mIU/L < 0.01\text{ mIU/L} < 0.01 mIU/L ), Elevated Free T4 and/or Free T3 . Features: heat intolerance, weight loss despite increased appetite, palpitations, fine tremor, hyperreflexia, diffuse vascular goiter with bruit, orbitopathy/exophthalmos , and pretibial myxedema.

Thyroid Storm: Life-threatening hypermetabolic crisis triggered by infection, surgery, or radioiodine. Manifests with hyperpyrexia ( > 40 ∘ C > 40^\circ\text{C} > 4 0 ∘ C ), marked tachycardia/atrial fibrillation, agitation, delirium, jaundice, and high-output heart failure.

Adrenal Pathophysiology:

Primary Adrenal Insufficiency (Addison's Disease): Autoimmune destruction of all three adrenal cortical zones (cortex). Deficiencies in cortisol, aldosterone, and androgens with elevated ACTH. Features: hyperpigmentation (pro-opiomelanocortin/ACTH cleavage to α \alpha α -MSH), orthostatic hypotension, hyponatremia, hyperkalemia, hypoglycemia.

Secondary Adrenal Insufficiency: Pituitary ACTH deficiency or abrupt withdrawal of chronic exogenous corticosteroid therapy leading to prolonged hypothalamic-pituitary-adrenal (HPA) axis suppression. Aldosterone secretion is preserved (regulated by RAAS, not ACTH); hyperpigmentation is absent.

Hypercortisolemia (Cushing's Syndrome): Excess glucocorticoids from exogenous steroid administration (most common), pituitary ACTH-secreting adenoma (Cushing's disease), or adrenal adenoma. Manifests with central adiposity, moon facies, buffalo hump, purple abdominal striae, proximal muscle wasting, osteoporosis, hypertension, and hyperglycemia.

  • Renal Pathophysiology +-------------------------------------------------------------------------+
  • | ACUTE KIDNEY INJURY (AKI) TAXONOMY |
  • +-------------------------------------------------------------------------+
  • | |
  • | [PRE-RENAL] (Hypoperfusion) [INTRINSIC] (Structural Damage)|
  • | - Volume depletion, HF, Sepsis - ATN: Ischemic / Nephrotoxic |
  • | - Afferent: NSAIDs (constrict) - AIN: Drug-allergic (PPI/ABX) |
  • | - Efferent: ACEi/ARBs (dilate) - Glomerulonephritis |
  • | - BUN:Cr > 20:1, FeNa < 1% - Muddy brown casts, FeNa > 2% |
  • | |
  • | [POST-RENAL] (Obstruction) ----------------> BPH, Stones, Neoplasm |
  • | |
  • +-------------------------------------------------------------------------+
  • 1. Acute Kidney Injury (AKI): Pre-Renal, Intrinsic, and Post-Renal

KDIGO defines AKI as an increase in serum creatinine by ≥ 26.5 μ mol/L \ge 26.5\,\mu\text{mol/L} ≥ 26.5 μ mol/L within 48 hours, a ≥ 1.5 \ge 1.5 ≥ 1.5 -fold rise above baseline within 7 days, or urine volume < 0.5 mL/kg/h < 0.5\text{ mL/kg/h} < 0.5 mL/kg/h for 6 hours.

Pre-Renal AKI (Hemodynamic/Hypoperfusion):

Renal parenchyma remains structurally intact. Decreased effective circulating arterial volume (hypovolemia, congestive heart failure, cirrhosis) lowers renal perfusion pressure below autoregulatory thresholds ( < 80 mmHg < 80\text{ mmHg} < 80 mmHg MAP).

Glomerular Hemodynamics: Autoregulation normally maintains GFR via prostaglandin-mediated afferent arteriolar vasodilation and angiotensin II-mediated efferent arteriolar vasoconstriction .

Drug Interference: NSAIDs block vasodilatory prostaglandins (constricting afferent arterioles), while ACE inhibitors / ARBs block angiotensin II (dilating efferent arterioles), precipitously dropping intraglomerular hydrostatic pressure and GFR.

Laboratory Profile: BUN : SCr > 20 : 1 \text{BUN}:\text{SCr} > 20:1 BUN : SCr > 20 : 1 , Fractional Excretion of Sodium ( FeNa \text{FeNa} FeNa ) < 1 % < 1\% < 1% , Urine Sodium < 20 mmol/L < 20\text{ mmol/L} < 20 mmol/L , high urine osmolality ( > 500 mOsm/kg > 500\text{ mOsm/kg} > 500 mOsm/kg ), hyaline casts.

Intrinsic / Intrarenal AKI (Structural Parenchymal Damage):

Acute Tubular Necrosis (ATN; ∼ 85 % \sim 85\% ∼ 85% of intrinsic AKI): Caused by prolonged severe ischemia (untreated pre-renal state) or nephrotoxins (aminoglycosides, iodinated radiocontrast agents, amphotericin B, cisplatin). Sloughing of tubular epithelial cells into lumens causes intratubular obstruction, back-leak of filtrate, and loss of tubular concentrating ability. Laboratory Profile: Muddy brown granular casts , FeNa > 2 % \text{FeNa} > 2\% FeNa > 2% , Urine Sodium > 40 mmol/L > 40\text{ mmol/L} > 40 mmol/L , low urine osmolality ( < 350 mOsm/kg < 350\text{ mOsm/kg} < 350 mOsm/kg ).

Acute Interstitial Nephritis (AIN): Type IV cell-mediated hypersensitivity reaction within the renal interstitium induced by drugs ( beta-lactams, ciprofloxacin, sulfonamides, proton pump inhibitors, NSAIDs ). Classical triad (seen in < 30 % < 30\% < 30% ): low-grade fever, maculopapular rash, peripheral eosinophilia; urinalysis shows WBC casts , pyuria, and eosinophiluria.

Acute Glomerulonephritis: Immune complex deposition causing glomerular basement membrane inflammation, hematuria, proteinuria, and dysmorphic RBC casts .

Post-Renal AKI (Urinary Tract Obstruction):

Mechanical obstruction to urinary outflow at the ureteral, bladder neck, or urethral level (benign prostatic hyperplasia [BPH], nephrolithiasis, pelvic tumors, neurogenic bladder, or anticholinergic medication toxicity).

Increased retrograde hydrostatic pressure within Bowman's capsule opposes glomerular filtration, reducing net GFR.

2. Chronic Kidney Disease and Mineral-Bone Disorder (CKD-MBD)

CKD is defined as persistent abnormalities of kidney structure or function (eGFR < 60 mL/min / 1.73 m 2 < 60\text{ mL/min}/1.73\,\text{m}^2 < 60 mL/min /1.73 m 2 or urinary albumin-to-creatinine ratio [ACR] ≥ 3.0 mg/mmol \ge 3.0\text{ mg/mmol} ≥ 3.0 mg/mmol ) for ≥ 3 months \ge 3\text{ months} ≥ 3 months . +-------------------------------------------------------------------------+

  • | PATHOGENESIS OF CKD-MBD CASCADE |
  • +-------------------------------------------------------------------------+
  • | |
  • | 1. Nephron Loss -> Decreased GFR -> Renal Phosphate Retention |
  • | | |
  • | v |
  • | 2. Elevated Serum Phosphate & Increased FGF-23 Secretion |
  • | | |
  • | v |
  • | 3. Downregulation of Renal 1-alpha-hydroxylase (CYP27B1) |
  • | | |
  • | v |
  • | 4. Impaired Synthesis of Active Calcitriol [1,25-(OH)2-Vitamin D3] |
  • | | |
  • | v |
  • | 5. Reduced Intestinal Calcium Absorption -> True Hypocalcemia |
  • | | |
  • | v |
  • | 6. Parathyroid Chief Cell Stimulation -> Secondary Hyperparathyroidism |
  • | | |
  • | v |
  • | 7. Excessive PTH -> High Bone Turnover, Osteodystrophy, Calcification |
  • | |
  • +-------------------------------------------------------------------------+

CKD-MBD Mechanism:

As functional nephron mass declines, renal clearance of phosphate decreases, leading to hyperphosphatemia .

Elevated phosphate stimulates osteocytes to secrete Fibroblast Growth Factor 23 (FGF-23) .

Elevated FGF-23 and damaged renal parenchyma downregulate renal 1 α 1\alpha 1 α -hydroxylase (CYP27B1) , severely blunting the conversion of 25-hydroxyvitamin D into active calcitriol (1,25-dihydroxyvitamin D) .

Diminished calcitriol reduces active intestinal absorption of calcium, producing hypocalcemia .

Hyperphosphatemia, hypocalcemia, and calcitriol deficiency stimulate parathyroid gland chief cells to produce excessive Parathyroid Hormone (PTH) , resulting in Secondary Hyperparathyroidism .

Chronically elevated PTH mobilizes calcium and phosphorus from skeletal reserves (renal osteodystrophy, osteitis fibrosa cystica) and promotes metastatic vascular and soft-tissue calcification (accelerating cardiovascular mortality).

  • Gastrointestinal and Hepatic Pathophysiology
  • 1. Peptic Ulcer Disease (PUD) and GERD

Gastroesophageal Reflux Disease (GERD): Driven by transient lower esophageal sphincter relaxations (TLESRs), hypotensive basal LES resting tone, hiatal hernia, delayed gastric emptying, and impaired esophageal acid clearance. Acid, pepsin, and bile contact esophageal squamous epithelium, causing inflammation, erosion, and potential metaplasia to specialized columnar epithelium ( Barrett's Esophagus , a premalignant lesion for esophageal adenocarcinoma).

Peptic Ulcer Disease (PUD): Mucosal break ≥ 5 mm \ge 5\text{ mm} ≥ 5 mm in diameter extending through the muscularis mucosae.

Helicobacter pylori Infection: Microaerophilic, Gram-negative bacterium producing bacterial urease (converts urea into ammonia and CO 2 \text{CO}_2 CO 2 ​ , buffering gastric acid to permit bacterial colonization). Induces chronic active gastritis, secretes cytotoxins (CagA, VacA), breaks down protective mucosal mucus barriers, and increases gastrin secretion.

NSAID-Induced Mucosal Injury: Systemic non-selective inhibition of Cyclooxygenase-1 ( COX-1 ) depletes mucosal cytoprotective prostaglandins ( PGE 2 , PGI 2 \text{PGE}_2, \text{PGI}_2 PGE 2 ​ , PGI 2 ​ ). This suppresses bicarbonate secretion, reduces mucosal blood flow, impairs mucus synthesis, and diminishes epithelial cell turnover.

2. Inflammatory Bowel Disease (IBD): Crohn's vs Ulcerative Colitis

Pathologic Feature Ulcerative Colitis (UC) Crohn's Disease (CD)

Anatomical Distribution Confined exclusively to the colon and rectum ; begins in rectum and extends continuously proximally Can affect any segment of the GI tract from mouth to anus; terminal ileum is the most common site ( > 70 % > 70\% > 70% )

Lesion Pattern Continuous mucosal inflammation without areas of spared tissue Discontinuous "skip lesions" with normal intervening mucosa

Depth of Inflammation Mucosal and submucosal only (superficial) Transmural (full-thickness through all wall layers)

Macroscopic Appearance Friable, diffuse erythema, superficial ulceration, pseudopolyps "Cobblestone" appearance , deep longitudinal fissure-like ulcers, wall thickening, creeping fat

Microscopic Hallmark Crypt abscesses, crypt distortion, architectural distortion Non-caseating granulomas ( > 30 % > 30\% > 30% ), transmural lymphoid aggregates

Clinical Complications Toxic megacolon , severe hemorrhage, high risk of colorectal adenocarcinoma Strictures (bowel obstruction) , fistulas (enterocutaneous, enterovesical), perianal fissures/abscesses, malabsorption (vitamin B12, bile acids)

Autoantibody Marker p-ANCA (perinuclear antineutrophil cytoplasmic antibodies; positive in 60 % to 70 % 60\%\text{ to }70\% 60% to 70% ) ASCA (anti-Saccharomyces cerevisiae antibodies; positive in 50 % to 60 % 50\%\text{ to }60\% 50% to 60% )

3. Hepatic Cirrhosis, Portal Hypertension, and ESLD Complications

Cirrhosis is the histopathological end-stage of chronic liver injury (viral hepatitis, alcohol, metabolic dysfunction-associated steatohepatitis [MASH]), characterized by diffuse hepatic fibrosis, replacement of normal architecture by regenerative parenchymal nodules, and vascular distortion. +-------------------------------------------------------------------------+

  • | PORTAL HYPERTENSION & CIRRHOSIS SEQUELAE |
  • +-------------------------------------------------------------------------+
  • | |
  • | Hepatic Fibrosis -> Increased Intrahepatic Resistance -> Portal HTN |
  • | | |
  • | |-- Splanchnic Vasodilation -> Hypovolemia -> RAAS -> [ASCITES] |
  • | | |
  • | |-- Portosystemic Collaterals -> Gastroesophageal [VARICES] |
  • | | |
  • | |-- Shunting & Hepatocyte Loss -> Ammonia -> [ENCEPHALOPATHY] |
  • | | |
  • | +-- Spleen Congestion -> Hypersplenism -> [THROMBOCYTOPENIA] |
  • | |
  • +-------------------------------------------------------------------------+

Portal Hypertension (HVPG > 5 mmHg > 5\text{ mmHg} > 5 mmHg ; clinically significant ≥ 10 mmHg \ge 10\text{ mmHg} ≥ 10 mmHg ): Fibrotic sinusoids and perisinusoidal stellate cell activation increase hepatic vascular resistance. Excessive nitric oxide production in the splanchnic circulation induces massive splanchnic vasodilation and hyperdynamic circulation.

Ascites: Splanchnic arterial vasodilation decreases effective arterial blood volume, triggering intense compensatory activation of the RAAS, sympathetic nervous system, and ADH. The resulting profound renal sodium and water retention, coupled with sinusoidal hypertension and hypoalbuminemia (reduced plasma oncotic pressure), drives transudation of fluid into the peritoneal cavity.

Spontaneous Bacterial Peritonitis (SBP): Spontaneous infection of ascitic fluid without an intra-abdominal surgically treatable source. Diagnosed when ascitic fluid paracentesis reveals an absolute neutrophil count (ANC) ≥ 250 × 10 6 / L \ge 250 \times 10^6/\text{L} ≥ 250 × 1 0 6 / L ( ≥ 0.25 × 10 9 / L \ge 0.25 \times 10^9/\text{L} ≥ 0.25 × 1 0 9 / L ).

Gastroesophageal Varices: Portal hypertension diverts portal blood flow into low-pressure portosystemic collateral vessels (esophagogastric junction, hemorrhoidal plexus, caput medusae). Varices dilate and rupture when wall tension exceeds tensile strength, causing life-threatening upper gastrointestinal hemorrhage.

Hepatic Encephalopathy (HE): Impaired hepatic parenchymal clearance and direct portosystemic shunting allow gut-derived neurotoxins (principally ammonia , generated by intestinal bacteria from dietary protein) to cross the blood-brain barrier. Ammonia is metabolized by astrocytes into glutamine, causing astrocyte swelling, cerebral edema, neurotransmitter imbalance (GABAergic upregulation), and clinical manifestations ranging from inverted sleep patterns to asterixis (flapping tremor) and coma.